Cargando…

A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease worldwide. Experimental and small clinical trials have demonstrated that angiotensin II blockers (ARB) may be anti-fibrotic in the liver. The aim of this randomised controlled trial was to assess whether treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	McPherson, Stuart, Wilkinson, Nina, Tiniakos, Dina, Wilkinson, Jennifer, Burt, Alastair D., McColl, Elaine, Stocken, Deborah D., Steen, Nick, Barnes, Jane, Goudie, Nicola, Stewart, Stephen, Bury, Yvonne, Mann, Derek, Anstee, Quentin M., Day, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395178/ https://www.ncbi.nlm.nih.gov/pubmed/28419124 http://dx.doi.org/10.1371/journal.pone.0175717

Ejemplares similares

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial
por: Houghton, David, et al.
Publicado: (2017)

Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease
por: Hardy, Timothy, et al.
Publicado: (2017)

Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017)

Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
por: Dyson, Jessica K, et al.
Publicado: (2014)

Deletion of Nardilysin Prevents the Development of Steatohepatitis and Liver Fibrotic Changes
por: Ishizu-Higashi, Shoko, et al.
Publicado: (2014)

Nutrigenetics-based intervention approach for adults with non-alcoholic fatty liver disease (NAFLD): study protocol for a randomised controlled feasibility trial
por: Haigh, Laura, et al.
Publicado: (2021)

Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice
por: Verbeek, Jef, et al.
Publicado: (2017)

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
por: Liu, Yang-Lin, et al.
Publicado: (2014)

Embedding assessment of liver fibrosis into routine diabetic review in primary care
por: Mansour, Dina, et al.
Publicado: (2021)

The role of angiotensin receptor blocker (losartan) on decreasing fibrotic process of corpora cavernosa in priapism model of wistar rats
por: Siregar, Safendra, et al.
Publicado: (2023)

Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study
por: Hallsworth, Kate, et al.
Publicado: (2019)

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan
por: Kawamura, Yusuke, et al.
Publicado: (2015)

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
por: Boyle, Marie, et al.
Publicado: (2019)

Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping
por: Hallsworth, Kate, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2014)

Republished: Non-alcoholic fatty liver disease: a practical approach to treatment
por: Dyson, J K, et al.
Publicado: (2015)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Losartan-Induced Angioedema: A Case Report
por: Mann, Henry, et al.
Publicado: (2023)

Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis
por: Min, Kyounghee, et al.
Publicado: (2023)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Anti‐fibrotic activity of Euglena gracilis and paramylon in a mouse model of non‐alcoholic steatohepatitis
por: Nakashima, Ayaka, et al.
Publicado: (2018)

Cellular senescence drives age-dependent hepatic steatosis
por: Ogrodnik, Mikolaj, et al.
Publicado: (2017)

Losartan-induced Pancreatitis
por: Anwar, Shamsuddin M, et al.
Publicado: (2019)

Paper 09: Revision rate following primary hip arthroscopy in patients given prophylactic oral losartan for the prevention of post-surgical fibrosis versus no losartan
por: Su, Chuck, et al.
Publicado: (2023)

An Incidental Finding of Eagle Syndrome Post-Losartan-Induced Angioedema
por: Mann, Henry, et al.
Publicado: (2023)

Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis
por: Chan, Wah Loong, et al.
Publicado: (2023)

Factors associated with engagement and adherence to a low-energy diet to promote 10% weight loss in patients with clinically significant non-alcoholic fatty liver disease
por: Scragg, Jadine, et al.
Publicado: (2021)

Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2)
por: Kunadian, Vijay, et al.
Publicado: (2018)

Is the combination of enalapril and losartan irrational?
por: Parmar, D.M., et al.
Publicado: (2008)

Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis
por: Jacobson, Ira M., et al.
Publicado: (2022)

Efficacy of Dietary Lipid Control in Healing High-Fat and High-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats
por: Tamada, Hazuki, et al.
Publicado: (2016)

Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations
por: Heinrichs, Daniel, et al.
Publicado: (2021)

Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions
por: Anstee, Quentin M., et al.
Publicado: (2021)

Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
por: Doward, Lynda C., et al.
Publicado: (2020)

Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling
por: Mungunsukh, Ognoon, et al.
Publicado: (2014)

Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study
por: O'Hara, Jamie, et al.
Publicado: (2020)

Dysregulated Bile Acid Synthesis, Metabolism and Excretion in a High Fat-Cholesterol Diet-Induced Fibrotic Steatohepatitis in Rats
por: Jia, Xiaofang, et al.
Publicado: (2013)

Secretome of senescent hepatic stellate cells favors malignant transformation from nonalcoholic steatohepatitis-fibrotic progression to hepatocellular carcinoma
por: Zhou, Yuan, et al.
Publicado: (2023)

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
por: Wai-Sun Wong, Vincent, et al.
Publicado: (2023)

A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
por: Govaere, Olivier, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cgijbc9av3nj0c25br2f7npvgv